Last Update 01 Apr 26

Fair value Increased 6.45%

AZN: 1H26 Trial Cluster Will Test Sustained Premium Earnings Expectations

AstraZeneca's updated analyst price target reflects a modest uplift, with the fair value estimate moving from £117.29 to £124.85 as analysts factor in refreshed models after recent results, a higher assumed future P/E of about 25x, and ongoing optimism around the earnings pipeline highlighted in recent research.

Analyst Commentary

Recent research on AstraZeneca has included a series of price target revisions, with several large banks updating their models following full year results and subsequent investor events. These updates have generally focused on refreshed earnings assumptions, pipeline expectations and how current trading levels compare with those revised fair value views.

Some analysts highlight AstraZeneca's earnings profile and pipeline as key parts of their updated work, including references to sector leading earnings growth and longer term earnings expectations that differ from broader market forecasts. Others flag that the timing and outcome of upcoming trial readouts, such as the SERENA 4 study referenced in sector research, could influence how investors think about specific therapy opportunities and future revenue mix.

There is also attention on the near term catalyst path. One large bank notes that events in the first half of 2026 could create a trickier setup for the shares, even as it sees the risk and reward balance as more attractive from the second half of 2026. For you as an investor, this kind of commentary frames AstraZeneca as an earnings and pipeline story where timing, data flow and execution around key programmes are central to how the equity case is viewed.

Across the research, many recent moves have involved higher price targets, expressed both in GBp for London listed shares and in US$ for the US listing. The absolute levels, such as targets around 16,000 GBp to 16,500 GBp or US$219, sit alongside continued references to valuation multiples like P/E. Analysts use these metrics to compare AstraZeneca against peers and its own history.

At the same time, research on related areas, including oral SERD therapies where AstraZeneca's SERENA 4 trial features in the discussion, underlines that competitor data and external study readouts could affect how investors frame specific drug opportunities. For you, that means sector research is watching not just AstraZeneca's own data, but also results from other companies that share similar therapeutic targets.

Bearish Takeaways

Bearish analysts point to the concentration of trial and regulatory catalysts around 1H26 as a source of event risk. They argue that any disappointment on data or approvals could put pressure on the current valuation and on assumed P/E multiples.
Some research flags execution risk around the pipeline, including the role of SERENA 4 and other first line oral SERD studies. These reports warn that weaker than expected outcomes or stronger competitor results could weigh on AstraZeneca's longer term growth profile.
Cautious views highlight that sector leading earnings growth expectations leave limited room for setbacks. Any delays, higher costs or slower uptake on key assets could therefore make it harder to justify premium valuation levels implied by recent price targets.
A few bearish analysts stress that, despite updated models and higher fair value estimates in some reports, the short term setup around upcoming data and market expectations leaves less margin for error on both execution and growth delivery.

What's in the News

AstraZeneca secured European Commission approval for Imfinzi plus FLOT chemotherapy as a perioperative treatment for resectable, early stage and locally advanced gastric and gastroesophageal junction cancers, following positive Phase III MATTERHORN trial data on event free and overall survival (company announcement).
Tozorakimab met the primary endpoint in both Phase III OBERON and TITANIA COPD trials, with reduced annualised moderate to severe exacerbation rates versus placebo on top of standard inhaled therapy, and is being advanced in additional Phase III studies including PROSPERO and MIRANDA (company announcement).
Multiple ENHERTU regulatory filings progressed, including a US Priority Review sBLA and EMA validation for HER2 positive breast cancer with residual invasive disease after neoadjuvant therapy, both supported by DESTINY Breast05 trial results (company announcement).
CALQUENCE plus venetoclax received US approval as the first all oral, fixed duration regimen for adults with CLL and SLL, based on the AMPLIFY Phase III trial, with detailed safety information outlined around infections, bleeding risk, cytopenias and cardiac events (company announcement).
French outlet La Lettre reported that Abivax granted AstraZeneca an exclusive period through 23 March to review confidential information and potentially formalise a takeover offer. Abivax indicated it could reopen talks with other bidders if no deal is reached after that date (La Lettre).

Valuation Changes

Fair Value: updated from £117.29 to £124.85, reflecting a higher modelled figure in the latest work.
Discount Rate: held steady at 7.20%, so the risk assumption in the model is unchanged.
Revenue Growth: adjusted from 4.27% to 4.53%, a small uplift in the expected $ top line growth rate used in the forecasts.
Net Profit Margin: moved from 23.11% to 18.55%, indicating a lower $ profitability assumption in the refreshed model.
Future P/E: raised from 19.89x to 25.41x, implying a higher valuation multiple applied to AstraZeneca's projected earnings.

27 views

Key Takeaways

Increased scrutiny on drug pricing and expiring patents threaten AstraZeneca's ability to sustain profit margins and reliable revenue growth.
Heavy R&D costs, global expansion, and geopolitical risk raise execution challenges that could pressure future earnings and cash flow stability.
Broad late-stage pipeline success, strategic global expansion, and technological investment are driving sustainable growth, margin improvements, and revenue stability while diversifying portfolio risk.

Catalysts

About AstraZeneca

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.What are the underlying business or industry changes driving this perspective?

The increasing emphasis by governments and insurers worldwide on containing healthcare costs is likely to intensify pressure on the pricing and reimbursement of AstraZeneca's medicines, particularly as the company's portfolio shifts toward more chronic disease therapies; this could cap future revenue growth and compress net margins as pricing power erodes steadily over the coming decade.
The looming expiration of patents on key blockbuster drugs like Tagrisso, Farxiga, and Imfinzi exposes AstraZeneca to biosimilar and generic competition that is almost certain to erode high-margin revenue streams, leading to a sharp decline in earnings and a structurally lower return on invested capital in later years.
Persistent regulatory and legislative scrutiny regarding pharmaceutical pricing, particularly in the United States and major European markets, is likely to result in more stringent controls or forced price concessions, further dampening AstraZeneca's ability to drive top-line and bottom-line expansion despite a robust new product pipeline.
The company's continued heavy investment in research and development, coupled with ambitious global expansion plans and large-scale manufacturing outlays, significantly increases execution risk; if clinical setbacks, integration challenges from acquisitions, or operational delays materialize, AstraZeneca's elevated cost base will put disproportionate pressure on future earnings and free cash flows.
Geopolitical uncertainty and the growing threat of protectionism-including tariffs, localization requirements, and supply chain disruptions-are set to inject greater volatility into international sales; as AstraZeneca is highly exposed to emerging markets, sudden policy shifts could undermine access, flatten revenue trajectories, and negatively impact long-term growth expectations.

AstraZeneca Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on AstraZeneca compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming AstraZeneca's revenue will grow by 4.5% annually over the next 3 years.
The bearish analysts assume that profit margins will increase from 17.4% today to 18.5% in 3 years time.
The bearish analysts expect earnings to reach $12.4 billion (and earnings per share of $8.05) by about April 2029, up from $10.2 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $18.7 billion.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 25.4x on those 2029 earnings, down from 29.5x today. This future PE is greater than the current PE for the GB Pharmaceuticals industry at 20.1x.
The bearish analysts expect the number of shares outstanding to grow by 0.06% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.2%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

AstraZeneca's pipeline continues to deliver an increasing number of late-stage regulatory approvals and positive Phase III trial readouts, supporting sustained revenue growth and margin expansion as these medicines reach market in oncology, rare disease, and biopharmaceuticals.
The company is benefitting from long-term secular tailwinds such as the aging global population and rising rates of chronic disease, which are enlarging the addressable healthcare market and bolstering demand for its therapies, translating to higher total revenue potential into and beyond 2030.
AstraZeneca's global diversification-shown by double-digit growth in the US and emerging markets, plus robust momentum in China despite some generic headwinds-reduces regional risk and supports stable revenue and earnings over the long term.
Significant investments in transformative technologies, digital/AI, and modern manufacturing are enhancing operational efficiency, driving operating leverage and supporting steady improvements in net margins, increasing long run earnings power.
Successful execution of business development, partnerships, and a broad expansion into new indications has both deepened AstraZeneca's product portfolio and reduced overreliance on individual blockbusters, decreasing long-term risk to revenue and net margins as products cycle through their life cycles.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for AstraZeneca is £124.85, which represents up to two standard deviations below the consensus price target of £165.49. This valuation is based on what can be assumed as the expectations of AstraZeneca's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £204.28, and the most bearish reporting a price target of just £114.27.
In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $67.1 billion, earnings will come to $12.4 billion, and it would be trading on a PE ratio of 25.4x, assuming you use a discount rate of 7.2%.
Given the current share price of £146.9, the analyst price target of £124.85 is 17.7% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on AstraZeneca?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Increasing Regulatory Controls And Patent Expiries Will Erode Value